Genetics of opioid dependence: A review of the genetic contribution to opioid dependence

Current Psychiatry Reviews

Volumn 10, Issue 2, 2014, Pages 156-167

  Mistry, Chetna J ^a   Bawor, Monica ^a   Desai, Dipika ^b   Marsh, David C ^c   Samaan, Zainab ^a,b,d  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

Dependence; Genes; Opioid; Opioid addiction; Opioidreceptors; SNP

Indexed keywords

OPIATE;

BDNF GENE; DRD2 GENE; DRD3 GENE; DRD4 GENE; GENE; GENETIC ANALYSIS; GENETIC EPIDEMIOLOGY; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HERITABILITY; HUMAN; MOLECULAR GENETICS; NGFB GENE; NRXN3 GENE; OPIATE ADDICTION; OPRD1 GENE; OPRK1 GENE; OPRM1 GENE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 84904729826     PISSN: 15734005     EISSN: 18756441     Source Type: Journal    
DOI: 10.2174/1573400510666140320000928     Document Type: Review

References (94)

1. Fischer B, Rehm J, Patra J, Cruz MF. Changes in illicit opioid use across Canada. CMAJ 2006; 175(11): 1385.
2. Fischer B, Cruz MF, Rehm J. Illicit opioid use and its key characteristics: A select overview and evidence from a Canadian multisite cohort of illicit opioid users (OPICAN). Can J Psychiatry 2006; 51(10): 624-34.
3. Fishbain D, Johnson S, Webster L, Greene L, Faysal J. Review of regulatory programs and new opioid technologies in chronic pain management: Balancing the risk of medication abuse with medical need. J Manag Care Pharm 2010; 16(4): 276-87.
4. Fischer B, Rehm J, Goldman B, Popova S. Non-medical use of prescription opioids and public health in Canada: An urgent call for research and interventions development. Can J Public Health 2008; 99(3): 182-4.
5. Hassouneh B, Centofanti JE, Reddy K. Pain management in postcraniotomy patients: A survey of canadian neurosurgeons. Can J Neurol Sci 2011; 38(3): 456-60.
6. Brattwall M, Turan I, Jakobsson J. Musculoskeletal pain: Prescription of NSAID and weak opioid by primary health care physicians in Sweden 2004-2008-A retrospective patient record review. J Pain Res 2010; 3: 131-5.
7. Rahn KA, McLaughlin PJ, Zagon IS. Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis. Brain Res 2011; 1381: 243-53.
8. Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the United States: Concerns and strategies. Drug Alcohol Depend 2006; 81(2): 103-7.
9. Fornasari D. Pain mechanisms in patients with chronic pain. Clin Drug Investig 2012; 32 (1): 45-52.
10. Narita M, Funada M, Suzuki T. Regulations of opioid dependence by opioid receptor types. Pharmacol Ther 2001; 89(1): 1-15.
11. Zhu H, Rockhold RW, Ho IK. The role of glutamate in physical dependence on opioids. Jpn J Pharmacol 1998; 76(1): 1-14.
12. Zhang H, Kranzler HR, Yang BZ, Luo X, Gelernter J. The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk. Mol Psychiatry 2008; 13(5): 531-43.
13. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ. Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain. J Neurosci 1987; 7(8): 2445-64.
14. Kalivas PW, Volkow ND. The neural basis of addiction: A pathology of motivation and choice. Am J Psychiatry 2005; 162(8): 1403-13.
15. Kalivas PW. The glutamate homeostasis hypothesis of addiction. Nat Rev Neurosci 2009; 10(8): 561-72.
16. Sher L. The role of endogenous opioids in the placebo effect in post-traumatic stress disorder. Forsch Komplementarmed Klass Naturheilkd 2004; 11(6): 354-9.
17. Contet C, Kieffer BL, Befort K. Mu opioid receptor: A gateway to drug addiction. Curr Opin Neurobiol 2004; 14(3): 370-8.
18. Bilkei-Gorzo A, Racz I, Michel K, et al. Control of hormonal stressreactivity by the endogenous opioid system Psycho-neuroendocrinology 2008; 33(4): 425-36.
19. Johnson SW, North RA. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci 1992; 12(2): 483-8.
20. O'Brien C. Addiction and dependence in DSM-V. Addiction 2011; 106(5): 866-7.
21. Krantz MJ, Mehler PS. Treating opioid dependence. Growing implications for primary care. Arch Intern Med 2004; 164(3): 277-88.
22. EMCDDA. Annual report on the state of the drugs problem in Europe. 2010; European Monitoring Centre for Drugs and Drug Addiction: Lisbon, Portugal.
23. Fischer B, Medved W, Gliksman L, Rehm J. Illicit opiate users in Toronto: A profile of current users. Addiction Research 1999; 7: 377-415.
24. Green TC, Grimes Serrano JM, Licari A, Budman SH, Butler SF. Women who abuse prescription opioids: Findings from the Addiction Severity Index-Multimedia Version Connect prescription opioid database. Drug Alcohol Depend 2009; 103(1-2): 65-73.
25. Fischer B, Rehm J, Brissette S, et al. Illicit opioid use in Canada: Comparing social, health, and drug use characteristics of untreated users in five cities (OPICAN Study). J Urban Health 2005; 82(2): 250-66.
26. Gomes T, Juurlink D, Moineddin R, et al. Geographical variation in opioid prescribing and opioid-related mortality in Ontario. Healthc Q 2011; 14(1): 22-4.
27. Denisco RC, Kenna GA, O'Neil MG, et al. Prevention of prescription opioid abuse: The role of the dentist. J Am Dent Assoc 2011; 142(7): 800-10.
28. Ruetsch C. Empirical view of opioid dependence. J Manag Care Pharm 2010; 16(1 Suppl B): S9-13.
29. White AG, Birnbaum HG, Mareva MN, et al. Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm 2005; 11(6): 469-79.
30. Chao J, Nestler EJ. Molecular neurobiology of drug addiction. Annu Rev Med 2004; 55: 113-32.
31. Jentsch JD, Taylor JR. Impulsivity resulting from frontostriatal dysfunction in drug abuse: Implications for the control of behavior by reward-related stimuli. Psychopharmacology (Berl) 1999; 146(4): 373-90.
32. Bush G, Vogt BA, Holmes J, et al. Dorsal anterior cingulate cortex: A role in reward-based decision making. Proc Natl Acad Sci U S A 2002; 99(1): 523-8.
33. Everitt BJ, Belin D, Economidou D, Pelloux Y, Dalley JW, Robbins TW. Neural mechanisms underlying the vulnerability to develop compulsive drug-seeking habits and addiction. Philos Trans R Soc Lond B Biol Sci 2008; 363(1507): 3125-35.
34. Guillin O, Diaz J, Carroll P, Griffon N, Schwartz JC, Sokoloff P. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 2001; 411(6833): 86-9.
35. Ross S, Peselow E. The neurobiology of addictive disorders. Clin Neuropharmacol 2009; 32(5): 269-76.
36. David V, Durkin TP, Cazala P. Differential effects of the dopamine D2/D3 receptor antagonist sulpiride on self-administration of morphine into the ventral tegmental area or the nucleus accumbens. Psychopharmacology (Berl) 2002; 160(3): 307-17.
37. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician 2008; 11(2 Suppl): S133-53.
38. Weinberg NZ. Risk factors for adolescent substance abuse. J Learn Disabil 2001; 34(4): 343-51.
39. Tsuang MT, Lyons MJ, Harley RM. Genetic and environmental influences on transitions in drug use. Behav Genet 1999; 29(6): 473-9.
40. Zapata JT, Katims DS, Yin Z. A two-year study of patterns and predictors of substance use among Mexican American youth. Adolescence 1998; 33(130): 391-403.
41. Kilpatrick DG, Acierno R, Saunders B, Resnick HS, Best CL, Schnurr PP. Risk factors for adolescent substance abuse and dependence: Data from a national sample. J Consult Clin Psychol 2000; 68(1): 19-30.
42. Ronel N, Levy-Cahana M. Growing-up with a substance-dependent parent: Development of subjective risk and protective factors. Subst Use Misuse 2011; 46(5): 608-19.
43. Chambers RA, Taylor JR, Potenza MN. Developmental neurocircuitry of motivation in adolescence: A critical period of addiction vulnerability. Am J Psychiatry 2003; 160(6): 1041-52.
44. Substance Abuse and Mental Health Services Administration. Results from the 2008 National Survey on Drug Use and Health: National Findings, in NSDUH Series H-36, O. o. A. Studies. Editor 2009; Rockville, MD, USA.
45. Koob G, Kreek MJ. Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am J Psychiatry 2007; 164(8): 1149-59.
46. Volkow ND, Wang GJ, Fowler JS, et al. Brain DAD2 receptors predict reinforcing effects of stimulants in humans: Replication study. Synapse 2002; 46(2): 79-82.
47. Dalley JW, Fryer TD, Brichard L, et al. Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science 2007; 315(5816): 1267-70.
48. Brewer JA, Potenza MN. The neurobiology and genetics of impulse control disorders: Relationships to drug addictions. Biochem Pharmacol 2008; 75(1): 63-75.
49. Webster LR, Webster RM. Predicting aberrant behaviors in opioidtreated patients: Preliminary validation of the opioid risk tool. Pain Med 2005; 6(6): 432-42.
50. Chou R, Fanciullo GJ, Fine PG, Miaskowski C, Passik SD, Portenoy RK. Opioids for chronic noncancer pain: Prediction and identification of aberrant drug-related behaviors: A reviewof the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain, 2009; 10(2): 131-46.
51. Cadoret RJ, Troughton E, O'Gorman TW, Heywood E. An adoption study of genetic and environmental factors in drug abuse. Arch Gen Psychiatry 1986; 43: 1131-6.
52. Kendler KS, Karkowski LM, Neale MC, Prescott CA. Illicit psychoactive substance use, heavy use, abuse, and dependence in a US population-based sample of male twins. Arch Gen Psychiatry 2000; 57(3): 261-9.
53. Tsuang MT, Bar JL, Harley RM, Lyons MJ. The Harvard Twin Study of Substance Abuse: What we have learned. Harv Rev Psychiatry 2001; 9(6): 267-79.
54. Xian H, Chantarujikapong SI, Scherrer JF, et al. Genetic and environmental influences on posttraumatic stress disorder, alcohol and drug dependence in twin pairs. Drug Alcohol Depend 2000; 61(1): 95-102.
55. Merikangas KR, Stolar M, Stevens DE, et al. Familial transmission of substance use disorders. Arch Gen Psychiatry 1998; 55(11): p. 973-9.
56. Neale MC. Mx: Statistical Modeling. 4 th ed. Department of Psychiatry, Medical College of Virginia 1997.
57. Tsuang MT, Lyons MJ, Meyer JM, et al. Co-occurrence of abuse of different drugs in men: The role of drug-specific and shared vulnerabilities. Arch Gen Psychiatry 1998; 55(11): 967-72.
58. Luquin-Piudo MR, Sanz P. Dopamine receptors, motor responses, and dopaminergic agonists. Neurologist 2011; 17(6 Suppl 1): S2-8.
59. Gerra G, Leonardi C, Cortese E, et al. Human kappa opioid receptor gene (OPRK1) polymorphism is associated with opiate addiction. Am J Med Genet B Neuropsychiatr Genet 2007; 144B(6): 771-5.
60. Kotler M, Cohen H, Segman R, et al. Excess dopamine D4 receptor (D4DR) exon III seven repeat allele in opioid-dependent subjects. Mol Psychiatry 1997; 2(3): 251-4.
61. Ebstein RP, Novick O, Umansky R, et al. Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of Novelty Seeking. Nat Genet 1996; 12(1): 78-80.
62. GeneCards Human Gene Database: DRD2 Gene. [cited: 2011 September 23]. Available from: http://www. genecards. org/cgibin/carddisp. pl?gene=DRD2.
63. Lawford BR, Young RM, Noble EP, et al. The D(2) dopamine receptor A(1) allele and opioid dependence: Association with heroin use and response to methadone treatment. Am J Med Genet 2000; 96(5): 592-8.
64. Hou QF, Li SB. Potential association of DRD2 and DAT1 genetic variation with heroin dependence. Neurosci Lett 2009; 464(2): 127-30.
65. Neville MJ, Johnstone EC, Walton RT. Identification and characterization of ANKK1: A novel kinase gene closely linked to DRD2 on chromosome band 11q23. 1. Hum Mutat 2004; 23(6): 540-5.
66. GeneCards Human Gene Database. 2011; Available from: http://www. genecards. org.
67. Duaux E, Gorwood P, Griffon N, et al. Homozygosity at the dopamine D3 receptor gene is associated with opiate dependence. Mol Psychiatry 1998; 3(4): 333-6.
68. Chien CC, Lin CH, Chang YY, Lung FW. Association of VNTR polymorphisms in the MAOA promoter and DRD4 exon 3 with heroin dependence in male Chinese addicts. World J Biol Psychiatry 2010; 11(2 Pt 2): 409-16.
69. Gilsbach S, Neufang S, Scherag S, et al. Effects of the DRD4 genotype on neural networks associated with executive functions in children and adolescents. Dev Cogn Neurosci 2012; 2(4): 417-27.
70. Li T, Xu K, Deng H, et al. Association analysis of the dopamine D4 gene exon III VNTR and heroin abuse in Chinese subjects. Mol Psychiatry 1997; 2(5): 413-6.
71. Kroslak T, Laforge KS, Gianotti RJ, Ho A, Nielsen DA, Kreek MJ. The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. J Neurochem 2007; 103(1): 77-87.
72. Kapur S, Sharad S, Singh RA, Gupta AK. A118g polymorphism in mu opioid receptor gene (oprm1): Association with opiate addiction in subjects of Indian origin. J Integr Neurosci 2007; 6(4): 511-22.
73. Bond C, LaForge KS, Tian M, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: Possible implications for opiate addiction. Proc Natl Acad Sci U S A 1998; 95(16): 9608-13.
74. Bart G, Heilig M, LaForge KS, et al. Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden. Mol Psychiatry 2004; 9(6): 547-9.
75. Befort K, Filliol D, Decaillot FM, Gaveriaux-Ruff C, Hoehe MR, Kieffer BL. A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J Biol Chem 2001; 276(5): 3130-7.
76. Mayer P, Rochlitz H, Rauch E, et al. Association between a delta opioid receptor gene polymorphism and heroin dependence in man. Neuroreport 1997; 8(11): 2547-50.
77. Franke P, Nöthen MM, Wang T, et al. Human delta-opioid receptor gene and susceptibility to heroin and alcohol dependence. Am J Med Genet 1999; 88(5): 462-4.
78. GeneCards Human Gene Database: OPRK1 Gene. 2011 September 23; Available from: http://www. genecards. org/cgibin/carddisp. pl? gene=OPRK1&snp=431&rf=/home/genecards/current/website/card disp. pl#snp.
79. Yuferov V, Fussell D, LaForge KS, et al. Redefinition of the human kappa opioid receptor gene (OPRK1) structure and association of haplotypeswith opiate addiction. Pharmacogenetics 2004; 14(12): 793-804.
80. Yuferov V, Levran O, Proudnikov D, Nielsen DA, Kreek MJ. Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. Ann N Y Acad Sci 2010; 1187: 184-207.
81. Xuei X, Dick D, Flury-Wetherill L, et al. Association of the kappaopioid system with alcohol dependence. Mol Psychiatry 2006; 11(11): 1016-24.
82. De Chiara V, Angelucci F, Rossi S, et al. Brain-derived neurotrophic factor controlscannabinoid CB1 receptor function in the striatum. J Neurosci 2010; 30(24): 8127-37.
83. Carvalho AL, Caldeira MV, Santos SD, Duarte CB. Role of the brain-derived neurotrophic factor at glutamatergic synapses. Br J Pharmacol 2008; 153 Suppl 1: S310-24.
84. De CidR, Fonseca F, Gratacòs M, et al. BDNF variability in opioid addicts and response to methadone treatment: Preliminary findings. Genes Brain Behav 2008. 7(5): 515-22.
85. Levran O, Peles E, Hamon S, et al. Nerve growth factor beta polypeptide (NGFB) genetic variability: Association with the methadone dose required for effective maintenance treatment. Pharmacogenomics J 2011; 12(4): 319-27.
86. Uhl GR, Liu Q-R, Walther D, Hess J, Naiman D. Polysubstance abuse-vulnerability genes: Genome scans for association, using 1, 004 subjects and 1, 494 single-nucleotide polymorphisms. Am J Hum Genet 2001; 69(6): 1290-300.
87. Heldt SA, Stanek L, Chhatwal JP, Ressler KJ. Hippocampusspecific deletion of BDNF in adult mice impairs spatial memory and extinction of aversive memories. Mol Psychiatry 2007; 12(7): 656-70.
88. Itoh K, Hashimoto K, Kumakiri C, Shimizu E, Iyo M. Association between brain-derived neurotrophic factor 196 G/A polymorphism and personality traits in healthy subjects. Am J Med Genet B Neuropsychiatr Genet 2004; 124B(1): 61-3.
89. Jia W, Shi JG, Wu B, Ao L, Zhang R, Zhu YS. Polymorphisms of brain-derived neurotrophic factor associated with heroin dependence. Neurosci Lett 2011; 495(3): 221-4.
90. Chen ZY, Patel PD, Sant G, et al. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J Neurosci 2004; 24(18): 4401-11.
91. Cheng CY, Hong CJ, Yu YW, Chen TJ, Wu HC, Tsai SJ. Brainderived neurotrophic factor(Val66Met) genetic polymorphism is associated with substance abuse in males. Brain Res Mol Brain Res 2005; 140(1-2): 86-90.
92. Stoltenberg SF, Lehmann MK, Christ CC, Hersrud SL, Davies GE. Associations among types of impulsivity, substance use problems and Neurexin-3 polymorphisms. Drug Alcohol Depend 2011; 119(3): e31-8.
93. Lachman HM, Fann CS, Bartzis M, et al. Genomewide suggestive linkage of opioid dependence to chromosome 14q. Hum Mol Genet 2007; 16(11): 1327-34.
94. Cui D, Zhang H, Yang BZ, et al. Variation inNGFB is associated with primary affective disorders in women. Am J Med Genet B Neuropsychiatr Genet 2011; 156B(4): 401-12.